Explainer
The Kimberly-Clark–Kenvue deal: terms, approvals and closing
Kimberly-Clark completed its purchase of Kenvue on 2 November 2026, a year after announcing a cash-and-stock deal that valued Kenvue at about $48.7 billion including debt.[1][2] Kenvue shareholders received $3.50 in cash and 0.14625 Kimberly-Clark shares for each share they held.[3] Kimberly-Clark paid about $6.7 billion in cash and issued about 281.1 million shares, and Kenvue's stock stopped trading on the NYSE.[4][5]
This page explains a completed corporate acquisition from the companies’ SEC filings. Figures such as synergies and combined revenue are the companies’ own projections. It is general information, not financial advice, and it does not recommend buying, selling or holding any stock.
The deal in brief
On 3 November 2025, Kimberly-Clark and Kenvue announced that Kimberly-Clark would buy all of Kenvue’s shares in a cash-and-stock deal. It valued Kenvue at an enterprise value of about $48.7 billion, based on Kimberly-Clark’s closing share price on 31 October 2025.[2] The two companies had signed the merger agreement the day before, on 2 November 2025.[6]
Kimberly-Clark completed the purchase on 2 November 2026, and Kenvue became a wholly owned subsidiary.[1] Kimberly-Clark says the combined company has 10 billion-dollar brands: Huggies, Listerine, Cottonelle, Neutrogena, Depend, Tylenol, Kleenex, Johnson’s Baby, Kotex and Scott.[7] For the general mechanics of deals like this, see how mergers and acquisitions work.
What shareholders received
Kenvue shareholders received $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share. At the 31 October 2025 price, that was worth $21.01 a share.[3] At announcement, the companies expected existing Kimberly-Clark shareholders to own about 54% of the combined company and Kenvue shareholders about 46%.[3]
At closing, Kimberly-Clark reported paying about $6.7 billion in cash and delivering about 281.1 million of its shares to Kenvue shareholders. It funded the cash with cash on hand, new debt and commercial paper.[4] When it announced the deal, it had said it would use its balance sheet, new debt and the previously announced sale of a 51% stake in its International Family Care and Professional business, backed by committed financing from JPMorgan Chase Bank.[8]
Approvals and timeline
- 3 November 2025: deal announced, with closing expected in the second half of 2026, subject to approvals.[2][9]
- 29 January 2026: shareholders of both companies approved the deal. On preliminary results, about 96% of Kimberly-Clark shares present voted to approve issuing the new shares. About 99% of Kenvue shares voted, or about 77% of all outstanding shares, backed the merger agreement.[10]
- 4 February 2026: the US Hart-Scott-Rodino antitrust waiting period expired.[11] The waiting period is explained in how antitrust merger review works.
- 2 November 2026: the deal closed. KVUE shares stopped trading on the NYSE at the market open, and the delisting took effect 10 days after the Form 25 filing.[1][5]
The combined company
The companies said Mike Hsu would be chairman and chief executive of the combined company, and that three Kenvue directors would join Kimberly-Clark’s board. The headquarters stays in Irving, Texas.[12] After closing, Kimberly-Clark said it would operate with four business segments and had a 13-member board.[13]
The companies projected that the combined business would have produced about $32 billion of net revenue and about $7 billion of adjusted EBITDA in 2025.[14] Kimberly-Clark expects about $2.1 billion of yearly run-rate synergies. That figure is about $1.9 billion of cost savings within three years plus about $500 million of extra profit from revenue synergies within four years, less about $300 million of reinvestment. It repeated that target at closing.[15] These are company projections, not results.
Deal terms and projections come from the companies’ filings and may differ from later results. Check Kimberly-Clark’s current SEC filings for up-to-date figures. For investment decisions, consider talking to a qualified, independent adviser.
Read next
How antitrust merger review works: HSR filings and second requests
How US agencies review mergers: the Clayton Act test, 2026 HSR thresholds, the 30-day wait, second requests, possible outcomes, and how EU review compares.
Questions readers ask
When did Kimberly-Clark complete the Kenvue acquisition?
On 2 November 2026. Kenvue became a wholly owned subsidiary of Kimberly-Clark.[1]
What did Kenvue shareholders get?
$3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share. At Kimberly-Clark's closing price on 31 October 2025, that was worth $21.01 a share.[3]
How big was the deal?
At announcement, the companies valued Kenvue at an enterprise value of about $48.7 billion. At closing, Kimberly-Clark reported paying about $6.7 billion in cash and delivering about 281.1 million of its shares.[2][4]
Who owns the combined company?
At announcement, the companies expected existing Kimberly-Clark shareholders to own about 54% and former Kenvue shareholders about 46% on a fully diluted basis.[3]
Is Kenvue stock still trading?
No. KVUE shares stopped trading on the New York Stock Exchange at the market open on 2 November 2026, and the delisting took effect 10 days after the Form 25 filing.[5]
Which brands does the combined company own?
Kimberly-Clark lists 10 billion-dollar brands, Huggies, Listerine, Cottonelle, Neutrogena, Depend, Tylenol, Kleenex, Johnson's Baby, Kotex and Scott.[7]
Sources
· 15 claims from 2 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Kimberly-Clark completed its acquisition of Kenvue on 2 November 2026, and Kenvue became a wholly owned subsidiary of Kimberly-Clark. confirmedas of 2026-11-02
- Kimberly-Clark Completes Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kenvue LLC (successor to Kenvue Inc.) Form 8-K, 2 November 2026 · Kenvue (SEC filing) · Primary source · Introductory Note (retrieved 2026-11-14)
- [2]
On 3 November 2025, Kimberly-Clark and Kenvue announced an agreement for Kimberly-Clark to buy all of Kenvue's shares in a cash-and-stock deal valuing Kenvue at an enterprise value of about $48.7 billion, based on Kimberly-Clark's closing share price on 31 October 2025. confirmedas of 2025-11-03
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [3]
Under the agreement, Kenvue shareholders were to receive $3.50 in cash plus 0.14625 Kimberly-Clark shares for each Kenvue share, worth $21.01 a share at Kimberly-Clark's 31 October 2025 closing price, leaving existing Kimberly-Clark shareholders with about 54% of the combined company and Kenvue shareholders with about 46%. confirmedas of 2025-11-03
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source · Transaction and Financial Details (retrieved 2026-11-14)
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source · Transaction and Financial Details (retrieved 2026-11-14)
- [4]
Kimberly-Clark reported paying about $6.7 billion in cash and delivering about 281.1 million of its shares to Kenvue shareholders, funding the cash with cash on hand, new debt and commercial paper borrowing. confirmedas of 2026-11-05
- Kimberly-Clark Form 10-Q for the quarter ended September 30, 2026 · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kimberly-Clark Form 10-Q for the quarter ended September 30, 2026 · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [5]
Kenvue's shares, which traded on the New York Stock Exchange as KVUE, stopped trading at the market open on 2 November 2026, and their delisting took effect 10 days after the Form 25 filing. confirmedas of 2026-11-02
- Kimberly-Clark Completes Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kenvue LLC (successor to Kenvue Inc.) Form 8-K, 2 November 2026 · Kenvue (SEC filing) · Primary source · Item 3.01 (retrieved 2026-11-14)
- [6]
Kenvue and Kimberly-Clark signed the merger agreement on 2 November 2025. confirmedas of 2026-11-02
- Kenvue LLC (successor to Kenvue Inc.) Form 8-K, 2 November 2026 · Kenvue (SEC filing) · Primary source · Introductory Note (retrieved 2026-11-14)
- [7]
Kimberly-Clark says the combined portfolio includes 10 billion-dollar brands, namely Huggies, Listerine, Cottonelle, Neutrogena, Depend, Tylenol, Kleenex, Johnson's Baby, Kotex and Scott. confirmedas of 2026-11-02
- Kimberly-Clark Completes Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [8]
Kimberly-Clark said it had committed financing from JPMorgan Chase Bank and planned to fund the cash part of the price from its balance sheet, new debt and the previously announced sale of a 51% interest in its International Family Care and Professional business. confirmedas of 2025-11-03
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [9]
When the deal was announced, and again after the shareholder votes, the companies said they expected it to close in the second half of 2026, subject to regulatory approvals and other conditions. confirmedas of 2026-01-29
- Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [10]
On 29 January 2026, shareholders of both companies approved the deal at special meetings; on preliminary results, about 96% of Kimberly-Clark shares present voted to approve issuing the new shares, and about 99% of Kenvue shares voted, about 77% of all outstanding shares, backed the merger agreement. confirmedas of 2026-01-29
- Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [11]
The US Hart-Scott-Rodino antitrust waiting period for the deal expired on 4 February 2026. confirmedas of 2026-11-05
- Kimberly-Clark Form 10-Q for the quarter ended September 30, 2026 · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [12]
The companies said Mike Hsu would be chairman and chief executive of the combined company, three Kenvue directors would join Kimberly-Clark's board at closing, and the combined company would keep Kimberly-Clark's headquarters in Irving, Texas. confirmedas of 2025-11-03
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source · Leadership, Governance and Headquarters (retrieved 2026-11-14)
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source · Leadership, Governance and Headquarters (retrieved 2026-11-14)
- [13]
After closing, Kimberly-Clark said it would operate with four business segments and that its board had 13 directors, including three former Kenvue directors. confirmedas of 2026-11-02
- Kimberly-Clark Completes Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kimberly-Clark Completes Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [14]
The companies projected that the combined business would have generated about $32 billion of net revenue and about $7 billion of adjusted EBITDA in 2025. confirmedas of 2025-11-03
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- [15]
Kimberly-Clark expects about $2.1 billion of run-rate synergies, made up of about $1.9 billion of cost savings within three years of closing and about $500 million of extra profit from revenue synergies within four years, partly offset by about $300 million of reinvestment; it reaffirmed that target at closing. confirmedas of 2026-11-02
- Kimberly-Clark Completes Acquisition of Kenvue (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
- Kimberly-Clark to Acquire Kenvue, Creating a $32 Billion Global Health and Wellness Leader (Form 8-K, Exhibit 99.1) · Kimberly-Clark Corporation (SEC filing) · Primary source (retrieved 2026-11-14)
Revision history (1)
- Page created.
Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: May 12, 2027.
Cite this page
"The Kimberly-Clark–Kenvue deal: terms, approvals and closing." ContentLora, updated Nov 14, 2026. https://contentlora.com/explain/kimberly-clark-kenvue-deal
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.